Trials / Withdrawn
WithdrawnNCT00530413
Study of Phenobarbital Inhibition of Catamenial Epilepsy
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Toledo Health Science Campus · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the effectiveness of low-dose Phenobarbital on the treatment of catamenial epilepsy. We propose that since the catamenial seizures are associated with the reduction in levels of GABA-enhancing allopregnanolone, short-term replacement with the GABAR-enhancing agent Phenobarbital will reduce the incidence of catamenial seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Phenobarbital | Phenobarbital will be given based on weight range |
| OTHER | Placebo | Placebo group |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2009-03-01
- First posted
- 2007-09-17
- Last updated
- 2014-12-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00530413. Inclusion in this directory is not an endorsement.